Artificial Tears Market Size Report 2032: Trends, Growth Opportunities, and Forecast by DelveInsight

DelveInsight's Artificial Tears Market Insights Report 2032 provides the current and forecast market analysis, individual leading Artificial Tears Companies market shares, challenges, Artificial Tears Market Drivers, barriers, trends, and key market Artificial Tears companies in the market.

To read more about the latest highlights related to the Artificial Tears Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/artificial-tears-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Artificial Tears Market Report
• In May 2025, Grifols received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to begin a Phase 2 clinical trial of GRF312 Ophthalmic Solution, an immunoglobulin (IG) eye drop being developed as a potential new treatment for dry eye disease (DED).
• The artificial tears market was valued at USD 2,496.66 million in 2024, growing at a CAGR of 8.16% during the forecast period from 2025 to 2032 to reach USD 4,662.67 million by 2032.
• North America is projected to hold the largest share of the Artificial Tears market in 2024, driven by several key factors.
• The leading Artificial Tears Companies such as Alcon Inc., Johnson & Johnson Services, Inc., Sight Sciences, AbbVie Inc., Théa Laboratories, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aldeyra Therapeutics, Inc., Viatris Inc., Tarsus Pharmaceuticals, Inc., MiBo Medical Group, Horus Pharma, OASIS Medical, Inc., VISUfarma, URSAPHARM Arzneimittel GmbH, Rohto Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Novaliq GmbH, AFT Pharmaceuticals, NovaBay Pharmaceuticals, Inc., and others.

To know more about why North America is leading the market growth in the Artificial Tears Market, get a snapshot @ Artificial Tears Market Outlook- https://www.delveinsight.com/sample-request/artificial-tears-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Artificial Tears Market Dynamics
According to a recent study published in the Ocular Surface (2024), in 2024, over 344 million people worldwide were affected by Dry Eye Disease (DED), underscoring a significant and growing disease burden. This rising prevalence is fueling the global demand for effective treatment options. Artificial tears play a vital role in relieving symptoms by moisturizing the eyes and reducing irritation, thereby driving the market growth. According to the data from DelveInsight Analysis (2025) revealed that in 2023 alone, over 2.3 million males and 8.3 million females in Japan were diagnosed with DED. In the United Kingdom, the burden was similarly high, with approximately 2.8 million mild, 1.3 million moderate, and 2 million severe cases reported. Additionally, a 2023 study published in Nature estimated that around 400 million individuals in China suffered from DED, equating to roughly one to two out of every five people.

Artificial Tears Market Segmentation Analysis
Artificial Tears Market by Product Type (Cellulose Derived Tears, Glycerin Derived Tears, Polyethylene Glycol & Propylene Glycol-Based Tears, and Others), Formulation (Eye Drops, Eye Ointments, and Others), Application (Dry Eye Disease Treatment, Allergies & Infections, and Others), Distribution Channel (Hospital & Retail Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

Get a sneak peek at the Artificial Tears Market Dynamics @ Artificial Tears Market Dynamics Analysis- https://www.delveinsight.com/sample-request/artificial-tears-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Artificial Tears Companies
Alcon Inc., Johnson & Johnson Services, Inc., Sight Sciences, AbbVie Inc., Théa Laboratories, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aldeyra Therapeutics, Inc., Viatris Inc., Tarsus Pharmaceuticals, Inc., MiBo Medical Group, Horus Pharma, OASIS Medical, Inc., VISUfarma, URSAPHARM Arzneimittel GmbH, Rohto Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Novaliq GmbH, AFT Pharmaceuticals, NovaBay Pharmaceuticals, Inc., and others.

Artificial Tears Market Drivers
The growing need for artificial tears is primarily driven by the rising global prevalence of the condition. A key contributing factor is the expanding geriatric population, which is more susceptible to developing dry eye symptoms due to age-related changes in tear production and ocular health. Additionally, increased product development and frequent new product launches among the leading market players are further supporting market momentum. These trends are creating a favorable environment for sustained growth, positioning the artificial tears market for robust and steady expansion from 2025 to 2032.

Which MedTech key players in the Artificial Tears Market are set to emerge as the trendsetter explore @ Artificial Tears Companies- https://www.delveinsight.com/sample-request/artificial-tears-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Artificial Tears Market Report
• Coverage- Global
• Forecast Period- 2025-2032
• Artificial Tears Companies- Alcon Inc., Johnson & Johnson Services, Inc., Sight Sciences, AbbVie Inc., Théa Laboratories, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aldeyra Therapeutics, Inc., Viatris Inc., Tarsus Pharmaceuticals, Inc., MiBo Medical Group, Horus Pharma, OASIS Medical, Inc., VISUfarma, URSAPHARM Arzneimittel GmbH, Rohto Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Novaliq GmbH, AFT Pharmaceuticals, NovaBay Pharmaceuticals, Inc., and others.

Interested in knowing the Artificial Tears Market by 2032? Click to get a snapshot of the Artificial Tears Market Trends- https://www.delveinsight.com/sample-request/artificial-tears-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Artificial Tears Market Report Introduction
2. Artificial Tears Market Executive Summary
3. Competitive Landscape
4. Regulatory Analysis
5. Artificial Tears Market Key Factors Analysis
6. Artificial Tears Market Porter's Five Forces Analysis
7. Artificial Tears Market Assessment
8. Artificial Tears Market Company and Product Profiles
9. KOL Views
10. Project Approach
11. About DelveInsight
12. Disclaimer & Contact Us

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.